LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) P/B ratio
As of 6 November 2026, LivaNova PLC (LIVN) trades at a P/B ratio of 3.6×. Over the past ten years it has ranged from 0.7× (January 2016) to 6.3× (November 2015); the current reading is higher than 94% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.8× | 47.02% |
| FY2024 | 1.9× | (10.84%) |
| FY2023 | 2.1× | (12.69%) |
| FY2022 | 2.4× | (28.53%) |
| FY2021 | 3.4× | 17.89% |
| FY2020 | 2.9× | 10.05% |
| FY2019 | 2.6× | (10.66%) |
| FY2018 | 3.0× | 39.09% |
| FY2017 | 2.1× | 63.49% |
| FY2016 | 1.3× | (79.10%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 3.1× | (9.95%) |
| Jun 2026 | 3.4× | 18.86% |
| Mar 2026 | 2.9× | 2.60% |
| Dec 2025 | 2.8× | 13.12% |
| 45 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| NEOG Neogen Corporation compare | 1.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 1.3× |
| ITGR Integer Holdings Corporation compare | 2.5× |
| BRKR Bruker Corporation compare | 3.7× |
| LIVN LivaNova PLC | 3.8× |
| AXGN AxoGen, Inc. compare | 5.4× |
| HAE Haemonetics Corporation compare | 6.2× |
| TXG 10x Genomics compare | 9.2× |
| IRTC iRhythm Holdings, Inc. compare | 24.4× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement